MicroPort CardioFlow Medtech Corp. (HK:2160)
:2160
Want to see HK:2160 full AI Analyst Report?
2160 Stock Chart & Stats
HK$1.25
HK$0.04(6.15%)
At close: 4:00 PM EST
HK$1.25
HK$0.04(6.15%)
Day’s Range― - ―
52-Week RangeHK$1.87 - HK$8.46
Previous CloseN/A
Volume546.00K
Average Volume (3M)8.07M
Market Cap
HK$2.43B
Enterprise ValueHK$552.07M
Total Cash (Recent Filing)HK$1.24B
Total Debt (Recent Filing)HK$232.24M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding1,273,311,400
10 Day Avg. Volume7,535,058
30 Day Avg. Volume8,069,439
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)10.44
Price to Sales (P/S)6.70
P/FCF Ratio-69.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)HK$2.18B
Bulls Say, Bears Say
Bulls Say
Solid Gross MarginsA ~55% gross margin indicates durable unit economics typical for device-plus-consumables models. High product-level margins provide long-term cushion to absorb SG&A and R&D while supporting eventual operating leverage as revenue scales and helping margin recovery once fixed costs are optimized.
Consumables-driven Revenue MixA business model tied to consumables and procedure volumes creates recurring, volume-linked revenue. This structural mix supports predictable repeat sales, improves revenue visibility over time, and can translate into stable lifetime customer value if clinical adoption and hospital tenders continue.
Consistent Top-line GrowthSteady revenue growth (8.7% YoY to 399.4M in 2025) signals ongoing market traction and demand for core products. Persistent top-line expansion supports scalability, provides a platform for margin improvement, and validates commercial channels and clinical adoption over the medium term.
Bears Say
Very High LeverageDebt at ~1.62B and debt/equity near 6.3x materially raises refinancing, covenant, and interest-rate risk. For a loss-making medtech firm, this constrains strategic flexibility, increases fixed financial obligations, and heightens vulnerability if procedure volumes or pricing pressure weaken.
Negative Free Cash FlowPersistently negative FCF (≈-38.3M) and slightly negative operating cash flow mean the business is not self-funding. Over months this requires external financing or asset sales, which is harder with elevated leverage and can dilute equity or increase debt costs, impairing long-term stability.
Widening Net LossesA net margin of roughly -33% demonstrates failure to convert revenue growth into sustainable profits. Continued operating losses limit retained earnings buildup, slow deleveraging, and force reliance on external capital, undermining the company's ability to invest in R&D and commercial expansion sustainably.
MicroPort CardioFlow Medtech Corp. News
2160 FAQ
What was MicroPort CardioFlow Medtech Corp.’s price range in the past 12 months?
MicroPort CardioFlow Medtech Corp. lowest stock price was HK$1.87 and its highest was HK$8.46 in the past 12 months.
What is MicroPort CardioFlow Medtech Corp.’s market cap?
MicroPort CardioFlow Medtech Corp.’s market cap is HK$2.43B.
When is MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date?
MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date is Sep 02, 2026 which is in 103 days.
How were MicroPort CardioFlow Medtech Corp.’s earnings last quarter?
Currently, no data Available
Is MicroPort CardioFlow Medtech Corp. overvalued?
According to Wall Street analysts MicroPort CardioFlow Medtech Corp.’s price is currently Overvalued.
Does MicroPort CardioFlow Medtech Corp. pay dividends?
MicroPort CardioFlow Medtech Corp. does not currently pay dividends.
What is MicroPort CardioFlow Medtech Corp.’s EPS estimate?
MicroPort CardioFlow Medtech Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MicroPort CardioFlow Medtech Corp. have?
MicroPort CardioFlow Medtech Corp. has 1,273,311,400 shares outstanding.
What happened to MicroPort CardioFlow Medtech Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MicroPort CardioFlow Medtech Corp.?
Currently, no hedge funds are holding shares in HK:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MicroPort CardioFlow Medtech Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corporation, a medical device company, researches, develops, and commercializes transcatheter and surgical solutions for structural heart diseases in the People's Republic of China. It offers Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set to target aortic, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company was founded in 2010 and is headquartered in Shanghai, China.
Technical Analysis
Peijia Medical Ltd.
―
AK Medical Holdings Ltd.
―
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
―
Yestar Healthcare Holdings Co Ltd
―
Venus Medtech (Hangzhou), Inc. Class H
―
Options Prices
Currently, No data available
---